We're excited to have you on board

White House Deal Just Triggered 80% Mean Reversion Setup ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

View in browser "Pfizer is at 9x earnings while its historical average is 18x – The math is screaming." Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance Editor's Note: When JC Parets makes an emergency prediction, I pay attention. His track record of calling every major market turn over the past 15 years - 2008, 2018, 2020 - before they happened speaks for itself. This isn't another market guru making wild claims. This is the analyst who warned us to ignore the crash narrative in May when everyone else was selling. Those who listened could have seen 14 winning opportunities since then. Now he's detected another government-mandated "Pivot Point" happening October 9th, and he believes this one could be even bigger. When someone with JC's proven track record calls for 2,000%+ potential returns, our readers deserve to hear it directly. That's why we're organizing this emergency briefing. Join us on October 8 at 2 p.m. ET — RSVP HERE - Ryan Fitzwater, Publisher Dear Reader, I've been pounding the table on two sectors all year: oil and gas, and pharmaceuticals. Both have been the most undervalued plays in the market. This week, that thesis just got a massive catalyst. The White House announced a breakthrough deal with Pfizer covering everything from tariffs to drug prices to U.S. manufacturing facilities. Pfizer, Eli Lilly, and Merck all ripped higher on the news. We grabbed quick profits on an Eli Lilly call option in the War Room, and our Pfizer position is sitting pretty in the portfolio. But here's what most investors are missing: this isn't just a news-driven pop. This is mean reversion math finally catching up to reality. The Numbers Don't Lie Pfizer's historical P/E ratio averages between 17-19x earnings. Right now? The stock is trading under 10x earnings. Let me spell this out: You're getting Pfizer at roughly half its normal valuation multiple. That's not a small discount – that's a mathematical anomaly begging to be corrected. Mean reversion is simple: when stocks get pushed to extremes, they eventually drift back toward their historical averages. It happens because extreme movements usually aren't sustainable. Investor sentiment, regulatory fears, or macroeconomic pressures that drive prices to ridiculous levels eventually normalize. SPONSORED Missed Nvidia? Buy Elon Musk’s “Silent Partner” In February 2016, when almost nobody was talking about artificial intelligence, Jeff Brown picked Nvidia as one of his favorite stocks. Shares have jumped by more than 22,000%... enough to turn $1,000 into more than $222,000. But if you missed out on Nvidia, here’s the good news… Jeff believes this Elon Musk “silent partner” could be the next big AI winner. Here's How This Plays Out The Setup: Pharmaceutical stocks got hammered on regulatory uncertainty and political noise. Fear drove valuations to basement levels that make no fundamental sense. The Catalyst: White House deals signal the political headwinds are shifting. Regulatory pressure isn't disappearing, but it's becoming manageable and predictable. The Math: If Pfizer simply reverts to its 17x earnings multiple (the low end of its historical range), you're looking at an 80% upside from current levels. That's not wishful thinking. That's arithmetic. YOUR ACTION PLAN Mean reversion isn't guaranteed to happen tomorrow, but it's one of the most reliable forces in markets over time. When quality companies with solid fundamentals trade at massive discounts to their historical norms, patient investors get paid. Pfizer isn't some speculative biotech. It's a dividend-paying cash machine trading like it's going out of business. The market is offering you blue-chip pharmaceutical exposure at bargain-basement prices. The opportunity is mathematical. The timing is now. The risk-reward is tilted heavily in your favor. For daily analysis like this and real-time trade alerts from the War Room, join us. INSIGHTS YOU MAY HAVE MISSED Follow These 3 Signals Before Making a Trade... SPOT Triggers Perfect Multi-Timeframe Setup Into Earnings Exactly Where the Market Will Go in October October Could Be The Most Profitable Month Ever SPONSORED The Cheap Bastard's Secret for Finding Great Stocks 99% of Investors Completely Ignore the Secret I Used to Find the Stock Above. Yet, It was a Gigantic Winner and Cost Next to Nothing. Discover Here My "Cheap Bastard's Trick" to Finding Great Stocks. Monument Traders Alliance, LLC You are receiving this email because you subscribed to Trade of the Day. To unsubscribe from Trade of the Day, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2025 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.